Skip to main content
Delfa

← All trials/NCT04866667

Completed

Observational Study of ASCVD Risks of Type 2 Diabetes in East China

Screening and Intervention of Arteriosclerotic Cardiovascular Disease in Type 2 Diabetes in Zhejiang Province

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

-

Actual enrollment

316

Study population

Cardiovascular disease, Chronic kidney disease, Obesity / overweight, Type 2 diabetes

Eligibility highlights

•HbA1c ≥7%•eGFR ≤60

Primary endpoint

•New-onset cardiovascular events

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04866667
Org study IDzjPPHNFM001

Timeline

Milestones

Study first posted2021-04-30actual
Study start2021-05-01actual
Primary completion2023-12-31actual
Study completion2024-05-31actual
Last update posted2026-04-13actual

Assets

Investigational agents

Liraglutide

Who this study enrolls

Cardiovascular diseaseChronic kidney diseaseObesity / overweightType 2 diabetes

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Type 2 diabetes patients over 18 years old with high risks of atherosclerotic cardiovascular disease

Inclusion criteria

•Type 2 diabetes
•HbA1c ≥7.0%
•Prior CVD cohort: age ≥50 and ≥1 of the following criteria.
-Prior MI
-Prior stroke or TIA
-Prior coronary, carotid or peripheral arterial revascularization
-N50% stenosis of coronary, carotid, or lower extremity arteries
-History of symptomatic CHD documented by Positive exercise stress test or any cardiac imaging or Unstable angina with ECG changes
-Asymptomatic cardiac ischemia Documented by positive nuclear imaging test, exercise test or dobutamine stress echo
-Chronic heart failure NYHA class II-III
-Chronic renal failure, eGFR <60 mL/min per 1.73m2 MDRD eGFR <60 mL/min per Cockcroft-Gault formula
•No Prior CVD group: Age ≥60 y and ≥1 of the following criteria.
-Microalbuminuria or proteinuria
-Hypertension and left ventricular hypertrophy by ECG or imaging
-Left ventricular systolic or diastolic dysfunction by imaging
-Ankle-brachial index b0.9

Exclusion criteria

•Type 1 diabetes
•other type diabetes
•Calcitonin ≥50 ng/L
•Use of a GLP-1 receptor agonist (exenatide, liraglutide or other) or pramlintide or any DPP-4 inhibitor within the 3 months prior to screening
•Use of insulin other than human NPH insulin or long-acting insulin analogue or premixed insulin within 3 months prior to screening. Shortterm use of other insulin during this period in connection with intercurrent illness is allowed, at Investigators discretion
•Acute decompensation of glycemic control
•An acute coronary or cerebrovascular event in the previous 14 d
•Currently planned coronary, carotid, or peripheral artery revascularization
•Chronic heart failure (NYHA class IV)
•Current continuous renal replacement therapy
•End-stage liver disease
•History of solid organ transplant or awaiting solid organ transplant
•Malignant neoplasm
•Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)
•Personal history of non-familial medullary thyroid carcinoma

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
3
Cardiometabolic biomarkers
2
Cardiovascular outcomes
1
Weight & body composition
1
Glycemic / diabetes
1

Cardiovascular outcomes

1 endpoint
Primary/protocol endpoint

New-onset cardiovascular events

Time frame:maximum 2 years

descriptive

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Body weight

Time frame:maximum 2 years

descriptive

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Blood glucose control

Time frame:maximum 2 years

descriptive

Cardiometabolic biomarkers

2 endpoints
Secondary/protocol endpoint

Lipid levels

Time frame:maximum 2 years

descriptive

Secondary/protocol endpoint

Blood pressure level

Time frame:maximum 2 years

descriptive

Other (unclassified)

3 endpoints
Secondary/protocol endpoint/low confidence

Fat Distribution Indicators

Time frame:maximum 2 years

descriptive

Secondary/protocol endpoint/low confidence

Fat Distribution Indicators

Time frame:maximum 2 years

descriptive

Secondary/protocol endpoint/low confidence

Microvascular complications

Time frame:maximum 2 years

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.